Litigation

Celgene Corporation v. Cipla

pending/settled

2:20-cv-07759

Court
D.N.J.

Patents at issue (1)

Defendants (1)

Summary

Cipla filed an Answer regarding ANDA No. 214618 for 2.5 mg Revlimid. The '498 patent was among the patents-in-suit per Cipla's answer.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Log in to generate analysis

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Log in to generate analysis

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Log in to generate analysis

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Log in to generate analysis

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).